Recognizing Gastroparesis Symptoms in Ozempic Users: A New York Guide

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Risk Awareness

If you're using Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering if these symptoms are related to gastroparesis. Decades of pharmacovigilance have established that drug-induced gastrointestinal side effects can sometimes signal more serious conditions. This guide outlines the key symptoms of gastroparesis associated with Ozempic and provides factual information to help you have an informed conversation with your healthcare provider.

Understanding Ozempic and Its Gastrointestinal Risks

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Among its known adverse effects, gastrointestinal reactions are prominent. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy. The mechanistic link between GLP-1 receptor agonists like Ozempic and gastroparesis involves the drug's pharmacological action: GLP-1 receptor agonists slow gastric emptying as part of their glucose-lowering effect. This delay can become pathological in susceptible individuals, leading to symptomatic gastroparesis. While the prescribing information for Ozempic does not explicitly list gastroparesis as a separate adverse reaction, it does report gastrointestinal adverse reactions including dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), gastroesophageal reflux disease (placebo 0%, Ozempic 0.5 mg 1.9%, Ozempic 1 mg 1.5%), and gastritis (placebo 0.8%, Ozempic 0.5 mg 0.8%, Ozempic 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis.

Legal Considerations for Ozempic Gastroparesis Claims in New York

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about the risk of developing gastroparesis. This gap may be relevant for patients who experience persistent gastrointestinal symptoms after starting Ozempic and later receive a diagnosis of gastroparesis. The timeline between exposure and documented harm is variable; gastrointestinal adverse reactions often occur during dose escalation, but chronic symptoms may develop over weeks to months of continued use. For affected patients in New York, settlement-related considerations may include the need to demonstrate that Ozempic use was a substantial factor in causing gastroparesis, that the manufacturer failed to provide adequate warnings about this risk, and that the patient suffered compensable harm. Legal claims may involve product liability theories such as failure to warn or design defect. Patients should consult with a qualified attorney to evaluate their individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its glucose-lowering effect. In some individuals, this delay can become pathological, leading to symptomatic gastroparesis. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Can I file a lawsuit in New York for Ozempic-related gastroparesis?

Yes, if you developed gastroparesis after taking Ozempic and suffered harm, you may have a legal claim. New York residents should consult with a qualified product liability attorney to evaluate their case, as claims may involve failure to warn or design defect theories.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.